Follow the dosing schedule your doctor gave you. The table below shows the recommended Esbriet dosing schedule for the 267 mg capsules or tablets.
You should always take Esbriet with food. Doing so may help reduce certain side effects, including dizziness or nausea. Taking Esbriet with food decreases how quickly Esbriet is absorbed. It also decreases the drug level of Esbriet in the blood.
After you are doing well with the 9 pills (267 mg each, yellow tablets or white capsules) of Esbriet a day, you and your doctor may want to talk about moving to a 3-tablet-per-day option.
Once you are doing well on 9 pills a day, ask your doctor if transitioning to 3 brown tablets is an option for you.
If you have questions about your Esbriet dose, talk to your doctor.
To make it easier to remember these points when taking Esbriet, you can write them down and keep them with your medicine.
Other important things about your Esbriet treatment.
Managing IPF is not always easy, but there are ways you can help stay focused and motivated.
Genentech’s educators are called Clinical Education Managers. They do not provide medical advice. If you have questions about your health or treatment, you are encouraged to contact your health care provider.
Zitter Health Insights. Policy & Access Tracking Tool for Idiopathic Pulmonary Fibrosis. Published September 2017.
Independent co-pay assistance foundations have their own rules for eligibility. We cannot guarantee a foundation will help you. We only can refer you to a foundation that supports your disease state. We do not endorse or show financial preference for any particular foundation. The foundations we refer you to are not the only ones that might be able to help you.
The Medicare Extra Help program is not a Genentech program. It is administered by the Social Security Administration. The co-pay amount for Medicare Extra Help changes each year.
This Esbriet $5 Co-pay Program is valid ONLY for patients with commercial insurance who have a valid prescription for a Food and Drug Administration (FDA)-approved indication of a Genentech medication. Patients using Medicare, Medicaid or any other federal or state government program to pay for their medications are not eligible.
Under the program, the patient will pay a co-pay. After reaching the maximum program benefit, the patient will be responsible for all out-of-pocket expenses.
All participants are responsible for reporting the receipt of all program benefits as required by any insurer or by law. No party may seek reimbursement for all or any part of the benefit received through this Program. The program is only valid in the United States and U.S. Territories. This program is void where prohibited by law and shall follow state restrictions in relation to AB-rated generic equivalents (e.g., MA, CA) where applicable. The patient, guardian, prescriber, hospital and any other person using the program agree not to seek reimbursement for all or any part of the benefit received by the patient through the offer of this program. Genentech reserves the right to rescind, revoke or amend the program without notice at any time. Additional terms and conditions apply. Please visit EsbrietCopay.com for the full list of Terms and Conditions.
To be eligible for free Genentech medicine from the Genentech Patient Foundation, insured patients who have coverage for their medicine must have exhausted all other forms of patient assistance (including the Esbriet $5 Co-pay Program and support from independent co-pay assistance foundations) and must meet certain financial criteria. Uninsured patients and insured patients without coverage for their medicine must meet different financial criteria.
Eligible patients will pay as little as $5 per valid prescription, subject to a maximum benefit of $25,000 for a 12-month period.
The information contained in this section of the site is intended for U.S. healthcare professionals only. Click "OK" if you are a healthcare professional.
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.